ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

ALT Altimmune Inc

7,20
0,00 (0,00%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Altimmune Inc ALT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 7,20 06:00:03
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
7,18 6,90 7,42 7,26 7,20
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
25.4.202423:24GLOBEAltimmune Statement on the Passing of Dr. Stephen Harrison
27.3.202412:00GLOBEAltimmune Announces Positive Lean Mass Preservation Data for..
27.3.202411:57IHMARKETNEWSU.S. Stock Index Futures Point to a Rebound, Oil See..
20.3.202412:30GLOBEAltimmune to Report Fourth Quarter and Full Year 2023..
14.2.202418:04EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202412:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06.2.202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.1.202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.1.202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.1.202400:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.1.202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.1.202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.1.202417:49EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05.1.202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.1.202413:30GLOBEAltimmune Announces Presentation of Pemvidutide Clinical..
08.12.202314:35GLOBEWater Tower Research US Climate Virtual Investor Conference:..
04.12.202314:35GLOBEWater Tower Research US Climate Investor Conference Agenda..
30.11.202322:28EDGAR2Form 8-K - Current report
30.11.202322:24GLOBEAltimmune Announces Positive Topline Results from MOMENTUM..
07.11.202322:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.11.202313:06EDGAR2Form 8-K - Current report
07.11.202313:00GLOBEAltimmune Announces Third Quarter 2023 Financial Results and..
31.10.202312:30GLOBEAltimmune to Report Third Quarter 2023 Financial Results and..
26.10.202314:15DJNAltimmune Gets FDA Fast-Track Designation for Pemvidutide in..
26.10.202313:30GLOBEAltimmune Granted Fast Track Designation by FDA for..
25.10.202313:30GLOBEAltimmune to Present New Data on the Anti-Inflammatory and..
17.10.202313:30GLOBEAltimmune to Participate at Two Upcoming Investor..
29.9.202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.9.202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.9.202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.9.202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.9.202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.9.202322:55EDGAR2Form 8-K - Current report
26.9.202313:30GLOBEAltimmune Announces Oral Presentation of Pemvidutide..
12.9.202313:30GLOBEAltimmune Announces Completion of Dosing in the Phase 2..
30.8.202313:30GLOBEAltimmune to Participate at Two Upcoming Investor..
16.8.202322:14EDGAR2Form ARS - Annual Report to Security Holders
16.8.202322:10EDGAR2Form DEF 14A - Other definitive proxy statements
16.8.202300:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.8.202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202313:04EDGAR2Form 8-K - Current report
10.8.202313:00GLOBEAltimmune Announces Second Quarter 2023 Financial Results..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock